164 related articles for article (PubMed ID: 23085173)
21. Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.
Galeazzi R; Massaccesi L; Piva F; Principato G; Laudadio E
J Mol Model; 2014 Mar; 20(3):2120. PubMed ID: 24562856
[TBL] [Abstract][Full Text] [Related]
22. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
23. Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat.
Morán A; Ortiz de Urbina AV; Martín ML; García M; Rodriguez-Barbero A; Dorado F; San Román L
Eur J Pharmacol; 2008 Sep; 592(1-3):133-7. PubMed ID: 18644367
[TBL] [Abstract][Full Text] [Related]
24. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
Miller KJ; Wacker DA
Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics simulations and docking studies on 3D models of the heterodimeric and homodimeric 5-HT(2A) receptor subtype.
Bruno A; Beato C; Costantino G
Future Med Chem; 2011 Apr; 3(6):665-81. PubMed ID: 21554074
[TBL] [Abstract][Full Text] [Related]
26. Molecular and pharmacological characterization of serotonin 5-HT2A and 5-HT2B receptor subtypes in dog.
Bonaventure P; Nepomuceno D; Miller K; Chen J; Kuei C; Kamme F; Tran DT; Lovenberg TW; Liu C
Eur J Pharmacol; 2005 Apr; 513(3):181-92. PubMed ID: 15862800
[TBL] [Abstract][Full Text] [Related]
27. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes.
Yonezawa A; Yoshizumi M; Ebiko M; Ise SN; Watanabe C; Mizoguchi H; Kimura Y; Sakurada S
Pharmacol Biochem Behav; 2008 Feb; 88(4):367-73. PubMed ID: 17936345
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
Shimada I; Maeno K; Kondoh Y; Kaku H; Sugasawa K; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2008 Mar; 16(6):3309-20. PubMed ID: 18083579
[TBL] [Abstract][Full Text] [Related]
29. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW
Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681
[TBL] [Abstract][Full Text] [Related]
30. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.
Green MP; McMurray G; Storer RI
Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086
[TBL] [Abstract][Full Text] [Related]
31. Structure-based identification of aporphines with selective 5-HT(2A) receptor-binding activity.
Munusamy V; Yap BK; Buckle MJ; Doughty SW; Chung LY
Chem Biol Drug Des; 2013 Feb; 81(2):250-6. PubMed ID: 23039820
[TBL] [Abstract][Full Text] [Related]
32. Pharmacophore-directed homology modeling and molecular dynamics simulation of G protein-coupled receptor: study of possible binding modes of 5-HT2C receptor agonists.
Zuo Z; Chen G; Luo X; Puah C; Zhu W; Chen K; Jiang H
Acta Biochim Biophys Sin (Shanghai); 2007 Jun; 39(6):413-22. PubMed ID: 17558446
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
[TBL] [Abstract][Full Text] [Related]
34. A new class of 5-HT
Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
[TBL] [Abstract][Full Text] [Related]
35. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists.
Braden MR; Parrish JC; Naylor JC; Nichols DE
Mol Pharmacol; 2006 Dec; 70(6):1956-64. PubMed ID: 17000863
[TBL] [Abstract][Full Text] [Related]
36. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
Yuzlenko O; Kieć-Kononowicz K
J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
[TBL] [Abstract][Full Text] [Related]
37. Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
Runyon SP; Mosier PD; Roth BL; Glennon RA; Westkaemper RB
J Med Chem; 2008 Nov; 51(21):6808-28. PubMed ID: 18847250
[TBL] [Abstract][Full Text] [Related]
38. Molecular cloning and pharmacological characterization of serotonin 5-HT(3A) receptor subtype in dog.
Jensen TN; Nielsen J; Frederiksen K; Ebert B
Eur J Pharmacol; 2006 May; 538(1-3):23-31. PubMed ID: 16647053
[TBL] [Abstract][Full Text] [Related]
39. Molecular modeling of the 3D structure of 5-HT(1A)R: discovery of novel 5-HT(1A)R agonists via dynamic pharmacophore-based virtual screening.
Xu L; Zhou S; Yu K; Gao B; Jiang H; Zhen X; Fu W
J Chem Inf Model; 2013 Dec; 53(12):3202-11. PubMed ID: 24245825
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A/2C partial agonists.
Hansen M; Jacobsen SE; Plunkett S; Liebscher GE; McCorvy JD; Bräuner-Osborne H; Kristensen JL
Bioorg Med Chem; 2015 Jul; 23(14):3933-7. PubMed ID: 25583099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
